Foghorn Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
FHTX$2.04+9.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $80,302 | $80,876 |
| Marketable securities | 75,920 | 78,018 |
| Restricted cash | — | 1,250 |
| Prepaid expenses and other current assets | 2,092 | 3,091 |
| Total current assets | 158,314 | 163,235 |
| Property and equipment, net | 1,289 | 1,915 |
| Restricted cash | 2,000 | 2,000 |
| Other assets | 21 | 4 |
| Operating lease right-of-use assets | 29,328 | 30,949 |
| Total assets | $190,952 | $198,103 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $2,174 | $4,266 |
| Accrued expenses and other current liabilities | 12,475 | 11,357 |
| Operating lease liabilities | 3,792 | 923 |
| Deferred revenue | 18,874 | 43,192 |
| Total current liabilities | 37,315 | 59,738 |
| Operating lease liabilities, net of current portion | 40,076 | 40,347 |
| Deferred revenue, net of current portion | 127,398 | 205,962 |
| Other liabilities | 247 | 556 |
| Total liabilities | 205,036 | 306,603 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 175,000,000 shares authorized at September 30, 2026 and December 31, 2025; 59,962,650 shares issued and outstanding at September 30, 2026 and 56,657,329 shares issued and outstanding at December 31, 2025 | 6 | 6 |
| Additional paid-in capital | 587,416 | 523,937 |
| Accumulated other comprehensive gain (loss) | (123) | 24 |
| Accumulated deficit | (601,383) | (632,467) |
| Total stockholders’ deficit | $(14,084) | $(108,500) |
| Total liabilities and stockholders’ deficit | $190,952 | $198,103 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.